BACKGROUND: Injectable depot medroxyprogesterone acetate (DMPA) is one of the most popular contraception methods in areas of high HIV seroprevalence. Evidence is accumulating that use of DMPA might be associated with an increased risk of HIV-1 acquisition by women; however, mechanisms of this association are not completely understood. The goal of this study was to gain insight into mechanisms underlying the possible link between use of DMPA and risk of HIV-1 acquisition, exploring transcription profiling of ectocervical tissues. METHODS: Healthy women received either DMPA (n = 31) or combined oral contraceptive (COC), which has not been linked to an increased risk of HIV acquisition (n = 32). We conducted a comparative microarray-based whole-genome transcriptome profiling of human ectocervical tissues before and after 6 weeks of hormonal contraception use. RESULTS: The analysis identified that expression of 235 and 76 genes was significantly altered after DMPA and COC use, respectively. The most striking effect of DMPA, but not COC, was significantly altered expression (mostly downregulation) of many genes strategically involved in the maintenance of mucosal barrier function; the alterations, as indicated by Ingenuity Pathway Analysis (IPA), were most likely due to the DMPA-induced estrogen deficiency. Furthermore, IPA predicted that transcriptome alterations related to ectocervical immune responses were in general compatible with an immunosuppressive effect of DMPA, but, in some women, also with an inflammatory-like response. CONCLUSION: Our results suggest that impairment of cervicovaginal mucosal integrity in response to DMPA administration is an important mechanism contributing to the potential increased risk of HIV-1 acquisition in DMPA users. TRIAL REGISTRATION: ClinicalTrials.gov NCT01421368. FUNDING: This study was supported by the United States Agency for International Development (USAID) under Cooperative Agreement GPO-A-00-08-00005-00.
BACKGROUND: Injectable depot medroxyprogesterone acetate (DMPA) is one of the most popular contraception methods in areas of high HIV seroprevalence. Evidence is accumulating that use of DMPA might be associated with an increased risk of HIV-1 acquisition by women; however, mechanisms of this association are not completely understood. The goal of this study was to gain insight into mechanisms underlying the possible link between use of DMPA and risk of HIV-1 acquisition, exploring transcription profiling of ectocervical tissues. METHODS: Healthy women received either DMPA (n = 31) or combined oral contraceptive (COC), which has not been linked to an increased risk of HIV acquisition (n = 32). We conducted a comparative microarray-based whole-genome transcriptome profiling of human ectocervical tissues before and after 6 weeks of hormonal contraception use. RESULTS: The analysis identified that expression of 235 and 76 genes was significantly altered after DMPA and COC use, respectively. The most striking effect of DMPA, but not COC, was significantly altered expression (mostly downregulation) of many genes strategically involved in the maintenance of mucosal barrier function; the alterations, as indicated by Ingenuity Pathway Analysis (IPA), were most likely due to the DMPA-induced estrogen deficiency. Furthermore, IPA predicted that transcriptome alterations related to ectocervical immune responses were in general compatible with an immunosuppressive effect of DMPA, but, in some women, also with an inflammatory-like response. CONCLUSION: Our results suggest that impairment of cervicovaginal mucosal integrity in response to DMPA administration is an important mechanism contributing to the potential increased risk of HIV-1 acquisition in DMPA users. TRIAL REGISTRATION: ClinicalTrials.gov NCT01421368. FUNDING: This study was supported by the United States Agency for International Development (USAID) under Cooperative Agreement GPO-A-00-08-00005-00.
Entities:
Keywords:
AIDS/HIV; Expression profiling; Innate immunity; Reproductive Biology; Sex hormones
Authors: Andrea Ries Thurman; Neelima Chandra; Nazita Yousefieh; Irina Zalenskaya; Thomas Kimble; Susana Asin; Christiane Rollenhagen; Sharon M Anderson; Betsy Herold; Pedro M M Mesquita; Nicola Richardson-Harman; Tina Cunningham; Jill L Schwartz; Gustavo F Doncel Journal: AIDS Res Hum Retroviruses Date: 2016-02-10 Impact factor: 2.205
Authors: Craig R Cohen; Anna-Barbara Moscicki; Mark E Scott; Yifei Ma; Stephen Shiboski; Elizabeth Bukusi; Ibrahim Daud; Anu Rebbapragada; Joelle Brown; Rupert Kaul Journal: AIDS Date: 2010-08-24 Impact factor: 4.177
Authors: Monette M Cotreau; Vargheese M Chennathukuzhi; Heather A Harris; Lixin Han; Andrew J Dorner; Glen Apseloff; Usha Varadarajan; Ellyn Hatstat; Marjorie Zakaria; Andrew L Strahs; Judy S Crabtree; Richard C Winneker; Scott A Jelinsky Journal: Maturitas Date: 2007-11-09 Impact factor: 4.342
Authors: Alexander S Zevin; Irene Y Xie; Kenzie Birse; Kelly Arnold; Laura Romas; Garrett Westmacott; Richard M Novak; Stuart McCorrister; Lyle R McKinnon; Craig R Cohen; Romel Mackelprang; Jairam Lingappa; Doug A Lauffenburger; Nichole R Klatt; Adam D Burgener Journal: PLoS Pathog Date: 2016-09-22 Impact factor: 6.823
Authors: Nirk E Quispe Calla; Rodolfo D Vicetti Miguel; Kristen M Aceves; Angelo Torres; Thomas L Cherpes Journal: Contraception Date: 2019-07-11 Impact factor: 3.375
Authors: Erica L Gollub; Heidi E Jones; Lauren J Ralph; Janneke H H M van de Wijgert; Nancy Padian; Zena Stein Journal: J Womens Health (Larchmt) Date: 2018-12-21 Impact factor: 3.017
Authors: Jeremy V Camp; Robert L Wilson; Morgan Singletary; James L Blanchard; Anna Aldovini; Robert W Kaminski; Edwin V Oaks; Pamela A Kozlowski Journal: Vaccine X Date: 2021-06-24
Authors: Nirk E Quispe Calla; Rodolfo D Vicetti Miguel; Linda Fritts; Christopher J Miller; Kristen M Aceves; Thomas L Cherpes Journal: Biol Reprod Date: 2020-08-04 Impact factor: 4.285
Authors: Maria Röhl; Annelie Tjernlund; Julie Lajoie; Gabriella Edfeldt; Frideborg Bradley; Sofia Bergström; Vilde Kaldhusdal; Alexandra Åhlberg; Anna Månberg; Kenneth Omollo; Geneviève Boily-Larouche; Muhammad Asghar; Douglas S Kwon; Julius Oyugi; Joshua Kimani; Peter Nilsson; Keith R Fowke; Kristina Broliden Journal: Vaccines (Basel) Date: 2021-03-04